January 21, 2022

Beyond Going Long

Complete UK News World

Corona Virus: Initial tests for the vaccine from Moderna had good results against Omicron

US drugmaker Moderna announced Monday that a booster dose of its coronavirus vaccine should also provide protection against the omicron coronavirus variant. The Associated Press reported it.

Initial laboratory data

Moderna wrote in a press release that the currently approved 50-mcg booster dose increased the level of antibodies that the omicron variant could destroy, nearly 37-fold compared to the case before it was administered. A dose of 100 mcg increased this level approximately 83-fold. They recommend this dose for people with weakened immune systems.

Moderna published preliminary lab data in a press release, which has not yet been professionally evaluated, according to the Associated Press. However, tests by the US National Institutes of Health (NIH) last week confirmed similar results.

Clinical trials of this vaccine from Moderna should begin in early 2022.

mRNA . technology

The Pfizer/BioNTech vaccine also showed a significant increase in omicron-capable antibodies in tests. Both vaccines (Pfizer and Moderna) use mRNA technology. The Associated Press recalls that many countries around the world use them in their vaccination campaigns.

The level of antibodies determines how well a vaccine can prevent infection with the coronavirus. However, these antibodies are only one component of the immune system’s defense, the AP recalls. Other studies have confirmed that vaccines protect against the dangerous course of the disease if a person is infected with the Corona virus.

See also  Corona Virus: Putin hopes that Sputnik V will protect him